# Kainova Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kainova-therapeutics

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.kainovatx.com/
- Total disclosed funding: $52M
- Latest round: Series B (Feb 10, 2026)
- Investors on record: 24

## About

Kainova Therapeutics Inc., f.k.a. Domain Therapeutics S.A., is focused on developing innovative therapies targeting G protein-coupled receptors (GPCRs) to meet unmet medical needs in immuno-oncology and inflammation. Founded in 2008 in Strasbourg, France by Pascal Neuville, Kainova Therapeutics Inc. develops GPCR-targeting therapies. The company has successfully navigated changes in strategy and has established partnerships with various pharmaceutical companies. In February 2026, Kainova Therapeutics Inc. raised CAD 32 million in series B funding led by Investissement Québec, with participation from CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Groupe, Schroders Capital, adMare BioInnovations, and Seido Capital. The CEO, Pascal Neuville, has been instrumental in guiding the company's operations since its inception, while founder Anggi Febrianty has played a pivotal role in its establishment. Domain Therapeutics specializes in developing GPCR-targeting therapies aimed at addressing significant medical needs in immuno-oncology and inflammation. Their proprietary candidates include DT-9081, an EP4 receptor antagonist, DT-7012, an anti-CCR8 depleting antibody, and DT-9046, a biased antagonist of PAR2. These therapies are meticulously crafted to enhance efficacy and improve patient outcomes by modulating the immune system. The company aims to deliver solutions in markets across North America and Europe, providing therapeutic products to pharmaceutical companies, healthcare providers, and patients. In 2023, Domain Therapeutics reported a revenue of EUR 3,601,258.30 and an EBITDA of EUR -15,390,268. The company generates revenue primarily through partnerships with leading pharmaceutical firms, which may involve collaborative research, licensing agreements, and milestone payments. Their core therapeutic offerings, including DT-7012 and DT-9046, are integral to their revenue structure, designed to support further investment and partnerships as they advance to clinical stages. The company will use the February 2026 funding to accelerate clinical development of its GPCR-targeting therapies for immuno-oncology and inflammation.

## Funding rounds

- Series B, Feb 10, 2026, $23M — Schroders Capital, Seventure Partners, Turenne Groupe, Investment Quebec, CTI Life Sciences, adMare Bioinnovations, Seido Capital, 3B Future Health Fund, Panacea Venture, Viva BioInnovator
- Series A, May 10, 2022, $14M — Schroders Capital, Seventure Partners, Omnes Capital, Turenne Groupe, CTI Life Sciences, adMare Bioinnovations, Seido Capital, 3B Future Health Fund, Panacea Venture, Viva BioInnovator
- Series A, Jul 6, 2012, $2.5M — Auriga Partners, Seventure Partners, SODIV, MI Airline
- Series A, Apr 7, 2009, $2.8M — Auriga Partners, Sofinnova Partners, Idinvest Partners, Andera Partners, Edmond de Rothschild Asset Management, Capital Grand Est, MI Airline
- Series B, May 1, 2004, $9.8M — Auriga Partners, Siparex, Sofinnova Partners, Idinvest Partners, Andera Partners, Truffle Capital, Sudinnova, CDC Entreprises, Amundi, Edmond de Rothschild Asset Management

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series B, Series A
- Siparex (https://capitalatlas.ai/funds/siparex) — Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B, Series A
- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series B, Series A
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series A
- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series B
- Sudinnova (https://capitalatlas.ai/funds/sudinnova) — Series B
- CDC Entreprises — Series B
- Amundi (https://capitalatlas.ai/funds/amundi) — Series B
- Edmond de Rothschild Asset Management (https://capitalatlas.ai/funds/edmond-de-rothschild-asset-management) — Series B, Series A
- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Series A
- MI Airline — Series A
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A, Series B
- SODIV — Series A
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A, Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series A, Series B
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series A, Series B
- adMare Bioinnovations (https://capitalatlas.ai/funds/admare-bioinnovations) — Series A, Series B
- Seido Capital (https://capitalatlas.ai/funds/seido-capital) — Series A, Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A, Series B
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A, Series B
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A, Series B
- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Series B